A5042729315- Dialysis and Renal Disease Management
- Healthcare Policy and Management
- Chronic Kidney Disease and Diabetes
- Health Systems, Economic Evaluations, Quality of Life
- Healthcare cost, quality, practices
- Diabetes Treatment and Management
- Potassium and Related Disorders
- Primary Care and Health Outcomes
- Global Health Care Issues
- Blood Pressure and Hypertension Studies
- Health disparities and outcomes
- Organ Donation and Transplantation
- SARS-CoV-2 and COVID-19 Research
- Acute Kidney Injury Research
- Renal Transplantation Outcomes and Treatments
- Radiation Dose and Imaging
- Chronic Disease Management Strategies
- Pharmaceutical Practices and Patient Outcomes
- Food Security and Health in Diverse Populations
- Renal and Vascular Pathologies
- Human Resource Development and Performance Evaluation
- Patient Satisfaction in Healthcare
- Healthcare Systems and Public Health
- Cardiovascular Health and Risk Factors
- Homelessness and Social Issues
Cornell University
2020-2025
Weill Cornell Medicine
2020-2025
The Rogosin Institute
2021-2024
University of California, San Francisco
2017-2023
San Francisco VA Health Care System
2019-2023
Cerebral Palsy Research Network
2020
Research Network (United States)
2020
San Francisco VA Medical Center
2020
Pediatric Nephrology of Alabama
2019
Icahn School of Medicine at Mount Sinai
2016-2017
Chronic kidney disease (CKD) causes substantial global morbidity and increases cardiovascular all-cause mortality. Unlike other chronic diseases with established strategies for screening, there has been no consensus on whether health systems governments should prioritize early identification intervention CKD. Guidelines evaluating managing CKD are available but have not universally adopted in the absence of incentives or quality measures prioritizing care. The burden falls disproportionately...
Importance Novel therapies for type 2 diabetes can reduce the risk of cardiovascular disease and chronic kidney progression. The equitability these agents’ prescription across racial ethnic groups has not been well-evaluated. Objective To investigate differences in sodium-glucose cotransporter-2 inhibitors (SGLT2i) glucagon-like peptide-1 receptor agonists (GLP-1 RA) among adult patients with by groups. Design, Setting, Participants Cross-sectional analysis data from US Veterans Health...
Cervantes, Lilia; Rizzolo, Katherine; Tummalapalli, Sri Lekha; Wainstein, Marina; Glasgow, Russell E.; Jolles, Mónica Pérez Author Information
Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) reduce kidney disease progression and mortality in patients with chronic (CKD), regardless of diabetes status. However, the prescribing patterns these novel therapeutics CKD population real-world settings remain largely unknown.
Improving the quality of CKD care has important public health implications to delay disease progression and prevent ESKD. National trends are not well established. Furthermore, it is unknown whether gaps in due lack physician awareness status patients or other factors.We performed a national, serial, cross-sectional study visits office-based ambulatory practices for adults with diagnosed from years 2006 2014. We assessed following indicators: (1) BP measurement, (2) uncontrolled...
To assess the prevalence and correlates of prescription sodium-glucose cotransporter 2 inhibitors (SGLT2i) and/or glucagon-like peptide 1 receptor agonists (GLP1-RA) in individuals with type diabetes mellitus (T2DM) without chronic kidney disease (CKD).This was a cross-sectional analyses SGLT2i GLP1-RA prescriptions from January 2019 to 31 December 2020 Veterans Health Administration System. The likelihood examined by presence or absence CKD predicted risks atherosclerotic cardiovascular...
Undocumented immigrants comprise an estimated 11 million of the US population. Access to health care for this community is limited; nearly 50%–70% lack insurance.1 can receive primary through safety-net clinics, such as federally qualified centers, and they emergency medical treatment mandated by Emergency Medical Treatment Active Labor Act (EMTALA). There are conditions, however, with treatments that do not fall into or care, strictly defined EMTALA. This case undocumented kidney failure....
Abstract Background In chronic kidney disease (CKD), assessment of both estimated glomerular filtration rate (eGFR) and albuminuria are necessary for stratifying risk determining the need nephrology referral. The Kidney Disease: Improving Global Outcomes clinical practice guidelines CKD recommend referral eGFR < 30 ml/min/1.73m 2 or urinary albumin/creatinine ratio ≥ 300 mg/g. Methods Using a national claims database US patients covered by commercial insurance Medicare Advantage, we...
Depression is common in patients with end-stage renal disease (ESRD) on hemodialysis (HD). Although, depression associated mortality, the effect of in-hospital outcomes has not been studied as yet.We analyzed National Inpatient Sample for trends and hospitalizations ESRD.The proportion ESRD doubled from 2005 to 2013 (5.01-11.78%). Hospitalized HD were younger (60.47 vs. 62.70 years, p < 0.0001), female (56.93 47.81%, white (44.92 34.01%, had higher comorbidities. However, there was a...
This cross-sectional study evaluates the stipulations of coverage under commercial, health insurance exchange, Veterans Affairs, Medicare, Medicaid, or other for canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin.
Background: Medicaid expansion substantially increased health insurance coverage, but its effect on the delivery of preventative care is unclear. Objective: The objective this study was to assess impact receipt 15 different measures preventive including cancer screening, cardiovascular risk reduction, diabetes care, and other primary measures. Research Design: We performed serial cross-sectional analysis Behavioral Risk Factor Surveillance System (BRFSS) survey data from 2012 2017. used a...
The finalized ESRD Treatment Choices (ETC) payment model was announced by the Centers for Medicare & Medicaid Services (CMS) on September 18, 2020.[1][1] Recognizing underutilization of home dialysis and kidney transplantation, CMS introduced ETC as part Advancing American
Providing high-quality patient-centered care is the central mission of dialysis facilities. Assessing quality and patient-centeredness necessary for continuous facility improvement. Based predominantly on readily measured items, current measures in emphasize biochemical utilization outcomes, with very few patient-reported items. Additionally, metrics often do not account patient preferences may compromise by limiting ability providers to individualize targets, such as adequacy, based...
1Division of Nephrology & Hypertension, Department Medicine, Weill Cornell New York, NY 2Division Healthcare Delivery Science Innovation, Population Health Sciences, 3The Rogosin Institute, 4University Pennsylvania, Philadelphia, PA 5Department General Internal University Colorado Anschutz Medical Campus, Aurora aCorresponding author: Sri Lekha Tummalapalli, MD, MBA, MAS, Division 402 East 67th Street, 10065, Ph: 646-962-8001, E-mail: [email protected]
ABSTRACT Background An adequate workforce is needed to guarantee optimal kidney care. We used the International Society of Nephrology Global Kidney Health Atlas (ISN-GKHA) provide an assessment global care workforce. Methods conducted a multinational cross-sectional survey evaluate capacity and assessed data on number adult paediatric nephrologists, trainees in nephrology shortages various cadres for Data are presented according ISN region World Bank income categories. Results Overall,...
Background: Kidney disease is a major global public health problem, and laboratory testing of kidney measures essential for diagnosis monitoring. The availability affordability tests across countries has not been systematically described. Methods: International Society Nephrology (ISN), in partnership with leaders Disease: Improving Global Outcomes (KDIGO) Controversies Conference, surveyed representative subset ISN-Global Health Atlas (ISN-GKHA) respondents from April to June 2020. We...
Upcoming alternative payment models Primary Care First (PCF) and Kidney Choices (KCC) incorporate capitated payments for chronic disease management. Prior research on the effect of management has shown mixed results. We assessed patient, physician, practice characteristics practices with capitation as majority revenue, evaluated association reimbursement quality care.